Arginine methylation is crucial for tumor maintenance. PRMT9 levels are elevated in acute myeloid leukemia, and its inhibition eradicates leukemia by diminishing arginine methylation of proteins involved in DNA damage response and RNA translation. This activates the cGAS–STING pathway, which triggers immune responses directed against leukemia. Epigenetic targeting of DNA-damage-response mechanisms may bolster anti-tumor immunity.
This is a preview of subscription content, log in via an institution to check access.
References
Dohner, H., Weisdorf, D. J. & Bloomfield, C. D. N. Engl. J. Med. 373, 1136–1152 (2015).
Vago, L. & Gojo, I. J. Clin. Invest. 130, 1552–1564 (2020).
Poulard, C., Corbo, L. & Romancer, M. L. Oncotarget 7, 67532–67550 (2016).
Wu, K., Niu, C., Liu, H. & Fu, L. Int. J. Oncol. 62, 1–17 (2023).
Hwang, J. W., Cho, Y., Bae, G.-U., Kim, S.-N. & Kim, Y. K. Exp. Mol. Med. 53, 788–808 (2021).
Yang, Y. & Bedford, M. T. Nat. Rev. Cancer 13, 37–50 (2013).
Zhu, Y. et al. Drug Resist. Updat. 72, 101016 (2024).
Gerhart, S. V. et al. Sci. Rep. 8, 9711 (2018).
Dong, H. et al. Nat. Cancer https://doi.org/10.1038/s43018-024-00736-x (2024).
Reisländer, T., Groelly, F. J. & Tarsounas, M. Mol. Cell 80, 21–28 (2020).
Gilioli, D. et al. Preprint at BioRxiv https://doi.org/10.1101/2022.11.17.515658 (2022).
Marin, I. et al. Cancer Discov. 13, 410–431 (2023).
Chen, H.-A. et al. Cancer Discov. 13, 432–453 (2023).
Gambacorta, V. et al. Cancer Discov. 12, 1449–1461 (2022).
Chibaya, L. et al. Nat. Cancer 4, 872–892 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Santoro, A., Di Micco, R. PRMT9 inhibition sparks immune responses in AML. Nat Cancer 5, 539–541 (2024). https://doi.org/10.1038/s43018-024-00753-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-024-00753-w
- Springer Nature America, Inc.